Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Enlivex ( (ENLV) ) is now available.
On December 18, 2025, Enlivex Therapeutics announced it will convene an Extraordinary General Meeting of Shareholders on February 3, 2026, at its offices in Ness Ziona, Israel, to seek investor approval for a series of significant corporate governance and capital structure changes. Shareholders will be asked to vote on amendments to the Articles of Association to change the company’s name to Enlivex Ltd. (or a similar name), introduce a classified board with three staggered director classes, and increase authorized share capital, as well as to approve updated exemption and indemnification agreements for directors and the CEO, an equity bonus in restricted share units for the executive chairman, and a reverse share split of ordinary shares at a ratio between 1-for-2 and 1-for-20 to be implemented within 12 months at the board’s discretion, moves that collectively signal a strategic effort to strengthen corporate defenses, enhance capital flexibility and address share price and listing considerations for stakeholders.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is an Israel-based biopharmaceutical company, listed in the United States and Israel, that develops immunotherapy treatments and is governed under Israeli corporate law, with its principal executive offices located in Ness Ziona, Israel.
Average Trading Volume: 3,801,728
Technical Sentiment Signal: Sell
Current Market Cap: $20.55M
For a thorough assessment of ENLV stock, go to TipRanks’ Stock Analysis page.